Investigación

Tratamiento del cáncer pediátrico

Buscador de publicaciones

Publicaciones

  • Monterrubio C, Paco-Mercader S, Vilà-Ubach M, Rodriguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J and Carcaboso AM.

    Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts

    PHARMACEUTICAL RESEARCH . 32(9): 2889-2900. Nº de citas: 10

    [doi:10.1007/s11095-015-1671-9]

  • Garzón M, García-Fructuoso G, Suñol M, Mora J and Cruz-Martínez O.

    Low-grade gliomas in children: single institutional experience in 198 cases

    CHILDS NERVOUS SYSTEM . 31(9): 1447-1459. Nº de citas: 8

    [doi:10.1007/s00381-015-2800-9]

  • Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, Del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pastó G, San-Segundo L, Vilà-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J and de Álava E.

    The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget . 6(22): 18875-18890. Nº de citas: 64

    [doi:10.18632/oncotarget.4303]

  • Piquer-Gibert M, Alsina L, Giner MT, Cruz-Martínez O, Ruiz Echevarria K, Domínguez-Sánchez O, Plaza-Martín AM, Arostegui JI, de Valles G, Juan Otero M and Martín-Mateos MA.

    Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency

    EUROPEAN JOURNAL OF PEDIATRICS . 174(8): 1069-1076. Nº de citas: 22

    [doi:10.1007/s00431-015-2508-6]

  • Morales-La Madrid A, Hashizume R and Kieran MW.

    Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic.

    Frontiers in oncology . 5: 148-148. Nº de citas: 48

    [doi:10.3389/fonc.2015.00148]

  • Mora J, Cruz-Martínez O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador-Hernandez H, Suñol M, Carrasco-Torrents R, Guillen-Quesada A, Mañé S and de Torres C.

    Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 17(7): 521-529. Nº de citas: 12

    [doi:10.1007/s12094-014-1273-8]

  • Cockle JV, Picton S, Levesley J, Ilett E, Carcaboso AM, Short S, Steel LP, Melcher A, Lawler SE and Brüning-Richardson A.

    Cell migration in paediatric glioma; characterisation and potential therapeutic targeting

    BRITISH JOURNAL OF CANCER . 112(4): 693-703. Nº de citas: 26

    [doi:10.1038/bjc.2015.16]

  • Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA, Quezada MA, Molinari V, Shaw ML, Perez-Somarriba M, Temelso S, Raynaud F, Ruddle R, Panditharatna E, Englinger B, Mire HM, Jiang L, Nascimento A, LaBelle J, Haase R, Rozowsky J, Neyazi S, Baumgartner AC, Castellani S, Hoffman SE, Cameron A, Morrow M, Nguyen QD, Pericoli G, Madlener S, Mayr L, Dorfer C, Geyeregger R, Rota C, Ricken G, Ligon KL, Alexandrescu S, Cartaxo RT, Lau B, Uphadhyaya S, Koschmann C, Braun E, Danan-Gotthold M, Hu L, Siletti K, Sundström E, Hodge R, Lein E, Agnihotri S, Eisenstat DD, Stapleton S, King A, Bleil C, Mastronuzzi A, Cole KA, Waanders AJ, Carcaboso AM, Schüller U, Hargrave D, Vinci M, Carceller F, Haberler C, Slavc I, Linnarsson S, Gojo J, Monje M, Jones C and Filbin MG.

    GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.

    Cancer Cell . : .

    [doi:10.1016/j.ccell.2024.08.006]